...
首页> 外文期刊>American Journal of Veterinary Research >Evaluation of orally administered famciclovir in cats experimentally infected with feline herpesvirus type-1
【24h】

Evaluation of orally administered famciclovir in cats experimentally infected with feline herpesvirus type-1

机译:口服泛昔洛韦在实验性感染1型猫疱疹病毒的猫中的评估

获取原文
获取原文并翻译 | 示例
           

摘要

Objective-To evaluate orally administered famciclovir for treatment of cats with experimentally induced disease attributable to feline herpesvirus type 1 (FHV-1)Animals-16 nonvaccinated specific-pathogen free catsProcedures-Cats were treated orally with famciclovir (90 mg/kg n = 10) or a similar volume of lactose (400 mg 6) 3 times/d for 21 days Cats were inoculated with FHV-1 and administered the first treatment dose on day 0 Disease score weight results of urinalysis serum biochemical analysis and CBC histologic conjunctivitis score herpetic DNA shedding goblet cell density anti FHV-1 antibody concentration and plasma penciclovi concentration were measuredResults-On days 4 to 18 following inoculation disease scores were lower in famciclovir treated cats than in lactose treated cats Lactose-treated cats decreased in weight during the first 7 days after inoculation but famciclovir-treated cats increased in weight throughout the study Percentage change in weight was greater in famciclovir-treated cats on days 7 and 14 than in lactose-treated cats Serum globulin concentration was lower on days 3 through 9 conjunctivitis histologic score was lower on day 14 herpetic DNA was shed less frecuently throughout the study goblet cell density was greater on day 21 and circulating anti FHV-1 antibody concentration at study end was lower in famciclovir-treated cats compared with these measurements in lactose-treated cats Approximate peak plasma penciclovir concentration was 2 0 mu g/mLConclusions and Clinical Relevance-Famciclovir administration improved outcomes for systemic ophthalmic clinicopathologic virologic and histologic variables in cats experimentally infected with FHV-1 Adjunctive topical mucinomimetic and antimicrobial treat merits may also be necessary (Am J Vet Res 2011 72 85-95)
机译:目的-评估口服泛昔洛韦治疗猫源性1型疱疹病毒(FHV-1)的实验性疾病的猫动物-16只未接种疫苗的无特定病原体的猫-口服泛昔洛韦(90 mg / kg n = 10 )或类似体积的乳糖(400 mg 6)/天3次/天,连续21天,每天给猫接种FHV-1,并在第0天给予第一个治疗剂量尿液分析血清生化分析和CBC组织学结膜炎评分疱疹的疾病评分权重结果结果测量了接种泛昔洛韦的猫在接种病后4至18天的分数低于乳糖处理的猫,而经乳糖处理的猫的体重在头7天下降了接种后,但泛昔洛韦治疗的猫在整个研究过程中体重增加在第7天和第14天接受ir处理的猫比在接受乳糖处理的猫中接受治疗的猫在第3至9天的血清球蛋白浓度降低,在第14天的结膜炎组织学评分降低与接受乳糖处理的猫中的测量值相比,接受泛昔洛韦的猫中研究的循环抗FHV-1抗体浓度更低,血浆喷昔洛韦的峰值浓度约为2 0μg/ mL。在实验上感染了FHV-1的猫的临床病理病毒学和组织学变量也可能是必要的,同时需要局部使用拟拟药物和抗菌药物治疗(Am J Vet Res 2011 72 85-95)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号